Delcath Systems (NASDAQ:DCTH) Director Bridget Martell Sells 22,500 Shares of Company Stock

Delcath Systems, Inc. (NASDAQ:DCTH) Director Bridget Martell sold 22,500 shares of Delcath Systems stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $21.71, for a total transaction of $488,475.00. Following the completion of the sale, the director owned 22,500 shares of the company’s stock, valued at $488,475. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Delcath Systems Price Performance

NASDAQ:DCTH traded down $0.85 during trading hours on Friday, hitting $20.53. 675,133 shares of the company were exchanged, compared to its average volume of 488,204. The stock has a market capitalization of $714.24 million, a price-to-earnings ratio of 128.31 and a beta of 0.62. Delcath Systems, Inc. has a 52-week low of $8.12 and a 52-week high of $22.51. The company’s 50 day moving average price is $15.80 and its 200-day moving average price is $12.65.

Delcath Systems (NASDAQ:DCTH) last issued its quarterly earnings results on Monday, November 9th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.26. The business had revenue of $35.10 million for the quarter, compared to analyst estimates of $25.99 million. Delcath Systems had a net margin of 6.05% and a return on equity of 5.56%. On average, equities analysts predict that Delcath Systems, Inc. will post 0.13 earnings per share for the current year.

Analyst Upgrades and Downgrades

DCTH has been the topic of a number of research analyst reports. BTIG Research boosted their price objective on shares of Delcath Systems from $21.00 to $25.00 and gave the company a “buy” rating in a report on Monday. Weiss Ratings upgraded Delcath Systems from a “hold (c-)” rating to a “hold (c+)” rating in a research note on Thursday. HC Wainwright lifted their price target on Delcath Systems from $32.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday. Wall Street Zen upgraded Delcath Systems from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, Zacks Research upgraded Delcath Systems from a “hold” rating to a “strong-buy” rating in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, Delcath Systems presently has a consensus rating of “Buy” and a consensus price target of $29.33.

Hedge Funds Weigh In On Delcath Systems

Several hedge funds and other institutional investors have recently bought and sold shares of DCTH. Integrated Wealth Concepts LLC purchased a new position in Delcath Systems during the 2nd quarter worth approximately $48,000. IFP Advisors Inc purchased a new stake in shares of Delcath Systems in the 2nd quarter valued at $52,000. Royal Bank of Canada boosted its holdings in shares of Delcath Systems by 14.8% in the 1st quarter. Royal Bank of Canada now owns 18,383 shares of the company’s stock valued at $170,000 after acquiring an additional 2,364 shares during the last quarter. Kopp Family Office LLC acquired a new stake in shares of Delcath Systems in the third quarter worth $450,000. Finally, Allspring Global Investments Holdings LLC acquired a new stake in shares of Delcath Systems in the first quarter worth $306,000. Institutional investors and hedge funds own 61.12% of the company’s stock.

Top Delcath Systems Stories

Investors following DCTH have been watching these stories:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and $36 price target, raising its FY2026 EPS estimate from a loss of $0.17 to earnings of $0.13, and its FY2027 estimate from $0.12 to $0.33. Its Q4 2026 loss forecast also narrowed. HC Wainwright estimates
• Positive Sentiment: A recent quarterly report substantially exceeded expectations: Delcath reported EPS of $0.17 versus analysts’ forecast of a $0.09 loss, and revenue of $35.1 million versus the $26.0 million consensus. Earnings report
• Negative Sentiment: An analyst reduced a Q2 EPS forecast for Delcath, a modest negative signal alongside the more favorable revisions from HC Wainwright. EPS forecast reduction

About Delcath Systems

Delcath Systems, Inc. is an oncology company focused on liver-directed treatments for cancers that have spread to the liver. Its technology uses percutaneous hepatic perfusion, a procedure that temporarily isolates the liver’s blood supply and circulates chemotherapy through the organ before filtering the blood and returning it to the patient. The company’s HEPZATO KIT combines melphalan with a specialized delivery system. The U.S. Food and Drug Administration approved it for certain adults with unresectable metastatic uveal melanoma involving the liver.